Senti Biosciences (SNTI) Proxy Filing summary

Executive summary

• The 2025 Annual Meeting will be held virtually on June 25, 2025, with voting on director elections and auditor ratification.

• Proxy materials are distributed electronically to reduce costs and environmental impact, with print copies available upon request.

• The company remains an emerging growth company, utilizing scaled disclosure and not required to hold advisory say-on-pay votes until at least December 31, 2026.

Voting matters and shareholder proposals

• Shareholders will vote to elect three Class III directors for three-year terms and to ratify KPMG LLP as the independent auditor for 2025.

• Shareholder proposals for the 2026 meeting must be received by December 31, 2025, for inclusion in the proxy statement.

• The board recommends voting in favor of all proposals.

Board of directors and corporate governance

• The board is divided into three classes with staggered terms; current nominees are Brenda Cooperstone, James Collins, and Feng Hsiung.

• Committees include Audit, Compensation, and Nominating and Corporate Governance, each with defined charters and independent members.

• Board diversity is considered, though no formal diversity policy exists.

• Directors are encouraged to attend annual meetings, and a code of conduct and insider trading policy are in place.